Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 11/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 4/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11212136 | 0.82 | NUDT1 (0.57) | FEN1ALOX5APNUDT1GRM4KDM4E | |
| SCHEMBL16618084 | 0.79 | FEN1 (0.44) | FEN1ALOX5APMAPT | |
| SCHEMBL31721266 | 0.73 | NUDT1 (0.49) | FEN1ALOX5APNUDT1GRM4KDM4E | |
| SCHEMBL12813082 | 0.72 | POLB (0.54) | FEN1ALOX5APNUDT1GRM4KDR | |
| SCHEMBL1892428 | 0.72 | MEN1 (0.50) | FEN1ALOX5APNUDT1KDM4EMAPT | |
| SCHEMBL16624984 | 0.71 | FEN1 (0.40) | FEN1ALOX5AP | |
| SCHEMBL2025837 | 0.71 | KDR (0.45) | FEN1ALOX5APNUDT1METKDR | |
| SCHEMBL18622659 | 0.70 | FEN1 (0.41) | FEN1ALOX5AP | |
| SCHEMBL3121960 | 0.70 | — | — | |
| SCHEMBL359919 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005737-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170073315-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073315-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | TYMS, UMPS, DPYD | FEN1 305/4885ALOX5AP 2322/4885NUDT1 5/4885 |
| US-10005737-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | TYMS, UMPS, DPYD | FEN1 305/4885ALOX5AP 2322/4885NUDT1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.